Form 4: Aclaris Therapeutics CEO Neal Walker Reports Stock Transactions
SEC Form 4 Filing
CEO Neal Walker of Aclaris Therapeutics reports acquisition and disposal of common stock related to restricted stock units.
Summary
- On May 1, 2025, Neal Walker, CEO of Aclaris Therapeutics, acquired 9,467 shares of common stock through the vesting of restricted stock units.
- On the same day, Walker disposed of 2,975 shares to satisfy tax withholding obligations at a price of $1.38 per share.
- Following these transactions, Walker directly owns 1,479,824 shares of Aclaris Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing detailing stock transactions. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's a standard practice for executives to receive and manage stock-based compensation.
Key Dates
| Date | Description |
|---|---|
| March 1, 2024 | Start date for vesting of restricted stock units in equal monthly installments over 15 months. |
| May 1, 2025 | Date of stock acquisition and disposal related to restricted stock units. |
| May 5, 2025 | Date of signature for the report. |
Keywords
Aclaris Therapeutics, Neal Walker, Form 4, Stock Transactions, Restricted Stock Units, Beneficial Ownership, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.